David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
David M. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the Ohio State University Comprehensive Cancer Center, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab (Avastin) as treatment of patients with platinum-agnostic ovarian cancer.
In the overall study population of 60 patients, the overall response rate (ORR) was 50%. Looking at it at the high expression folate receptor group, which accounted for half of the patient population versus the low expression folate receptor, the ORR is even more pronounced 64%, in the high folate receptor alpha cohort. When platinum sensitivity versus platinum resistance was assessed in the high expression folate receptor alpha group, the ORR was 69% versus 59%, respectively.
O’Malley states that what is even more exciting about the data is that the duration of response (DOR) persisted beyond 12 months in patients with high expression folate receptor alpha who were platinum-sensitive and approached 10 months among those who were platinum-resistant. In the population of patients with median expression folate receptor alpha, the DOR was 8 months.
Further, 32 of the 33 patients who had high expression folate receptor alpha had tumor shrinkage, which O’Malley says represents the most impressive waterfall plot he has seen over time.